Compare Novavax Inc (NVAX) vs Global X NASDAQ 100 Covered Call ETF (QYLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Global X NASDAQ 100 Covered Call ETF — how do they compare? Novavax Inc trades at $7.96 (market cap $1.31B), while Global X NASDAQ 100 Covered Call ETF trades at $18.16. The key difference: Global X NASDAQ 100 Covered Call ETF is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.
| NVAX | QYLD | |
|---|---|---|
Market Cap | $1.31B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $11.19 | $18.52 |
52-Week Low | $6.22 | $16.46 |
Enterprise Value | $889.30M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVAX trades at $7.95, up 0.76% on the day, with a bullish technical signal despite mixed indicators. The company reported a net income of $440.30M for 2025, a significant turnaround from prior losses, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Q2 2026 results and a raised revenue outlook, driven by licensing milestones with Sanofi.
The outlook is cautiously optimistic given strong analyst buy ratings (73.92%) and improved financials, but risks include persistent negative cash flows, high debt, and competitive vaccine market pressures. Investment appeal hinges on execution of partnerships and cost management to sustain profitability.
QYLD trades at $18.18, up 0.14% on the day, with a bullish technical signal from moving averages but bearish oscillators. The ETF offers a high distribution yield near 12% through covered call strategies on the Nasdaq-100, though historical data shows it has underperformed the index in strong bull markets. Recent dividends include $0.18 and $0.19 payouts in mid-2026.
Outlook is mixed: QYLD provides substantial income for risk-averse investors in sideways markets, but caps upside potential. Key risks include erosion of net asset value during rallies and competition from lower-fee alternatives. Analyst sentiment is divided, with some upgrades highlighting yield appeal amid volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Global X NASDAQ 100 Covered Call ETF
QYLD is an ETF that follows a covered call strategy on the NASDAQ 100 Index. The fund holds a long position in the stocks of the NASDAQ 100 and simultaneously writes (sells) call options on the index. The primary goal is to generate monthly income from the option premiums. This strategy can reduce portfolio volatility and provide income, but it limits potential capital appreciation from a significant rise in the NASDAQ 100 Index.
Read more on QYLD →
